Patent intelligence · US
US 8440722
Methods for concomitant administration of colchicine and a second active agent
Methods for concomitant administration of colchicine and a second active agent
Patent details — US 8440722
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 14, 2013
- Expiration
- May 9, 2033
- Applicant
- Takeda Pharmaceuticals U.S.A., Inc.
- Claims
- 2
- CPC classes
- A61K, A61K31/165, A61K31/496, A61P
Quick answer
US 8440722 (Methods for concomitant administration of colchicine and a second active agent) is held by Takeda Pharmaceuticals U.S.A., Inc.. Status: granted. Granted May 14, 2013. Expires May 9, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Takeda Pharmaceuticals U.S.A., Inc.
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61K, A61K31/165, A61K31/496, A61P, A61P19/02, A61P19/06
More from Takeda Pharmaceuticals U.S.A., Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428403
N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists
granted -
US 12421188
Heterocyclic compound and use thereof
granted -
US 12419890
Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
granted -
US 12415866
Monoclonal antibody inhibitor of Factor XIIa
granted -
US 12415782
Heterocyclic compound and use thereof
granted -
US 12409210
CNS delivery of therapeutic agents
granted -
US 12404237
Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives
granted -
US 12403154
Administration of sting agonist and checkpoint inhibitors
granted
Frequently asked questions
What is US patent 8440722?
US 8440722 (Methods for concomitant administration of colchicine and a second active agent) is held by Takeda Pharmaceuticals U.S.A., Inc.. Status: granted. Granted May 14, 2013. Expires May 9, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8440722?
Takeda Pharmaceuticals U.S.A., Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.
When does US 8440722 expire?
Our index shows an expiration date of May 9, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.